Evidence map›Paper›PMID 37849227›Full record

ReviewRecent patents on nanotechnology2025

Nano-approaches and Recent Advancements in Strategies to Combat Challenges Associated with Thyroid Cancer Therapies.

Gurmehar Singh, Jatin Rathee, Triveni, Neha Jain, Upendra Nagaich, Shreya Kaul, Manisha Pandey, Bapi Gorain

Abstract readReview
PubMed Publisher
In one paragraph

Review in Recent patents on nanotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 2 citations in OpenAlex.

  1. Review
  2. Review
  3. Synthesis of AgInSDiscover oncology · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Gurmehar SinghDepartment of Pharmaceutics, Amity Institute of Pharmacy, Amity University, Noida, U.P., India.
Jatin RatheeDepartment of Pharmaceutics, Amity Institute of Pharmacy, Amity University, Noida, U.P., India.
TriveniDepartment of Pharmaceutics, Amity Institute of Pharmacy, Amity University, Noida, U.P., India.
Neha JainDepartment of Pharmaceutics, Amity Institute of Pharmacy, Amity University, Noida, U.P., India.ORCID 0000-0003-3827-5598
Upendra NagaichDepartment of Pharmaceutics, Amity Institute of Pharmacy, Amity University, Noida, U.P., India.
Shreya KaulDepartment of Pharmaceutics, Amity Institute of Pharmacy, Amity University, Noida, U.P., India.
Manisha PandeyDepartment of Pharmaceutical Sciences, Central University of Haryana, Mahendergarh, 123031, India.
Bapi GorainDepartment of Pharmaceutical Sciences and Technology, Birla Institute of Technology, Mesra, Ranchi, 835215, India.
Amity University · INBirla Institute of Technology, Mesra · INCentral University of Haryana · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The prevalence of thyroid cancer (TC) is more common in women and is up to 43% in patients aged between 45-65 years. The battle against TC is hampered by the lack of effective diagnostic and therapeutic approaches. The effectiveness of surgical procedures, such as thyroidectomy and nutraceutical treatments, are accompanied by several difficulties and still require further research. Alternatively, the DNA-damaging traditional model of chemotherapy is linked to poor solubility, untoward systemic effects, and associated cytotoxicity, instituting an urgent need to establish a specialized, factual, and reliable delivery tool. In order to overcome the limitations of conventional delivery systems, nanotechnology-based delivery tools have shown the potential of articulating endless inherent implementations. The probable benefits of emerging nanotechnology-based diagnostic techniques include rapid screening and early illness diagnosis, which draws investigators to investigate and assess the possibility of this treatment for TC. Subsequently, organic (e.g., liposomes, polymer-based, and dendrimers) and inorganic (e.g., gold, carbon-based, mesoporous silica, magnetic, and quantum dots) NPs and hybrids thereof (liposome-silica, chitosan-carbon, and cell membrane-coated) have been projected for TC biomarker screening, therapy, and detection, providing better outcomes than traditional diagnostic and treatment techniques. Therefore, this review aims to offer a broad perspective on nanoplatform in TC, accompanied by present and potential future treatment options and screening techniques; including the innovative patents utilized in the realm of thyroid cancer using nanocarriers. The goal of cancer therapy has traditionally been to "search a thorn in a hayloft"; therefore, this article raises the possibility of treating TC using nano-oncotherapeutics, which might be useful clinically and will encourage future researchers to explore this tool's potential and drawbacks.

Indexed as

Antineoplastic AgentsNanomedicineNanoparticlesNanotechnologyThyroid NeoplasmsDrug Delivery SystemsHumansLiposomesPatents as TopicAntineoplastic AgentsLiposomesconventional delivery.DNA-damaging modelnanocarriersNanotechnologyscreening techniquestarget-specific therapythyroid cancer

Identifiers

PMID37849227
OpenAlexW4387728330

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.